INHIBRX BIOSCIENCES INC (INBX)
Health Care · biotechnology · NASDAQ
Inhibrx Biosciences is a clinical-stage biotechnology company leveraging advanced protein engineering to develop targeted therapeutic candidates for complex diseases.
What INHIBRX BIOSCIENCES INC does
Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on the development of therapeutic candidates for conditions with high unmet medical needs. The company utilizes its proprietary protein engineering platform to create novel biologics, including multivalent antibodies and therapeutic proteins.
Themes: biotechnology, drug development, therapeutic biologics, protein engineering
Fundamentals
- Price$92.76 as of 2026-10-08 close
- Market cap$1.4B as of 2026-08-07 (share count; price 2026-10-08)
- 1-year return+176.0% 2025-10-08 close $33.61 → 2026-10-08 close $92.76
- P/En/a negative earnings
- Net margin-10773.5% FY2025, SEC XBRL
- ROE-1752.2% FY2025, SEC XBRL
- Debt / equity12.58 as of 2026-09-02
- Revenue growth (YoY)+550.0% FY2025 vs FY2024, SEC XBRL
- Revenue CAGR (3y)-15.0% SEC XBRL
- Beta1.28 as of 2026-09-02
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How INBX compares in its sector
- net profit marginbottom 10% 430 covered Health Care peers, as of 2026-09-02
- operating marginbottom 10% 417 covered Health Care peers, as of 2026-09-02
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How INHIBRX BIOSCIENCES INC looks technically
INHIBRX BIOSCIENCES INC (INBX) is trading 1.6% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 307 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30). It just made a new 20-day low, its first since 2026-08-17, breaking below its recent trading range. It is 40.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 1.6% above its 200-day average, the long-term trend line — a longer-term uptrend | +1.6% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $103.00 | $103.00 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $91.26 | $91.26 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Wave structure | its recent swings can be read as a completed three-part upward correction — a pullback in the A-B-C shape Elliott-wave chartists use; the labelling fails if price closes above 117.14. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible three-wave upward correction, complete (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 307 trading days ago — a "golden cross", a bullish long-term signal | 307 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 18, below the 25 that marks a real trend), though sellers have been pushing harder than buyers lately — pressure, not a trend | 18.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 36, neither overbought (above 70) nor oversold (below 30) | 35.6 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($90.15 to $117.14) — its "stochastic" reading is 10 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 9.7 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 22 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $155.29 | $155.29 |
|---|---|---|
| From the 52-week high | it is 40.3% below its 52-week high (its highest price of the past year) | -40.3% |
| Above the 52-week low | it is 229.4% above its 52-week low (its lowest price of the past year) | +229.4% |
| Below the 52-week high | it is 40.3% below its highest point of the past year | 40.3% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-08-17, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 28 trading days ago | 28 sessions |
| All-time high | its highest closing price on record is $155.29 (set on 2026-04-22) | $155.29 |
| Given back of the 52-week move | over the past year its closes ranged ($28.36 to $141.84), and it has given back roughly a third of its rise from last year’s low — 43% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $68.08 to $71.71. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 43.3% |
| From the all-time high | it is 40.3% below its all-time high | -40.3% |
| Nearest price level | it is trading 1.7% below a resistance level at $94.34 — a price it turned at three times since 2025-12-08, most recently on 2026-09-08. Since 2024-10-08 it has 14 such levels below the current price and 2 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.7% |
| All-time low | its lowest closing price on record is $7.67 (set on 2022-06-16) | $7.67 |
| Above the all-time low | it is 1109.4% above its all-time low | +1,109% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 79% of it) | 21st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $6.29 between its high and its low — about 6.8% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $6.29 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $89.92 and $114.07 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $89.92 – $101.99 – $114.07 |
| Typical daily range (% of price) | its price moves about 6.8% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.8% |
| Stretch from the 200-day average | it is trading 0.2 daily ranges above its 200-day average price (1.7% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 0.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.64× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 7 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 7 sessions ago |
|---|---|---|
| Since a hammer | today, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | today |
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.2% |
|---|---|---|
| Open gap | it gapped 2.2% above the previous close 49 sessions ago and has not traded back through the level it left behind at 79.25 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.2% |
| Gap filled | a 3.5% gap up opened on 2026-09-29 has been "filled" 6 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 6 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 7 sessions in a row, a -11.51% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 7 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 19.9 percentage points (the stock lost 18.9% while the market gained 1.0%) | -19.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 8.3 percentage points (the stock lost 4.5% while the market gained 3.8%) | -8.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 28.1 percentage points (the stock gained 45.6% while the market gained 17.5%) | +28.1% |
| vs market, 12 months | over the past 12 months this stock beat the market by 161.0 percentage points (the stock gained 176.0% while the market gained 15.0%) | +161.0% |
Signal agreement
2
| Bullish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 4 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a fresh 20-day low, MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 11% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.5% of the share price. | -11.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 6% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $98.98 — a volume-weighted average of daily closes over 187 sessions, not a true tick-by-tick VWAP. | -6.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 14% below the average price paid since it last reported on 2026-08-13 (its 10-Q), so the typical buyer over that stretch is under water. That average is $108.42 — a volume-weighted average of daily closes over 40 sessions, not a true tick-by-tick VWAP. | -14.4% |
Price levels it has turned at before
INBX last closed at $92.76 on 2026-10-08. Since 2024-10-08 it has turned at 14 prices below its last close and 2 above; the 3 nearest below and the 2 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $94.34 | Resistance | 1.7% above the last close | turned there three times · 2025-12-08 to 2026-09-08 |
| $88.28 | Support | 4.8% below the last close | turned there twice · 2025-11-24 to 2026-02-09 |
| $86.52 | Support | 6.7% below the last close | turned there twice · 2025-11-05 to 2026-06-23 |
| $99.27 | Resistance | 7.0% above the last close | turned there twice · 2026-05-12 to 2026-06-18 |
| $85.01 | Support | 8.3% below the last close | turned there three times · 2026-02-19 to 2026-08-17 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a three-part upward correction — the A-B-C shape chartists use for a pullback — now complete.
This labelling fails — stops being a possible reading at all — if it closes above $117.14.
It is the only labelling that fits these swings, though its proportions are not the textbook ones. It was chosen from 3 labellings that survived the rules, counting shorter readings of the same bars.
This reading has stood for 8 trading days, since 2026-09-29.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Near 200-day moving-average support · Trading above the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · trendless / choppy (low ADX) · beating the market | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Mean price target$266.67 range $230.00 – $325.00; median $245.00
Analyst estimates, as of 2026-10-09. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for INBX
- Consensus EPS estimate-$2.36 next reporting period, as of 2026-10-09
- Estimate change, 30 days$0.00 from -$2.36, on 2026-09-04, 35-day window
- Readings revised upward14% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant ongoing losses and accumulated deficit with a history of negative cash flows from operations.","Substantial reliance on debt financing to fund ongoing research and development operations.","Clinical-stage nature of product pipeline carries inherent risks of failure in drug development and regulatory approval processes."]
What changed in the latest 10-Q
AI-assisted comparison of INBX's 10-Q filed 2026-05-14 against the prior one filed 2025-11-14.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing references fiscal year ended December 31, 2025 (vs. December 31, 2024 in older filing)
- Newer filing announces April 2026 interim data from Phase 1/2 colorectal cancer study with 45 evaluable patients, 20% ORR, 5.5 months median PFS, 87% disease control rate
- Newer filing states ozekibart maintains manageable safety profile with diarrhea, fatigue, nausea as most common treatment-related adverse events, largely Grade 1-2
- Newer filing notes 68% of patients presented with liver metastases at baseline with no significant liver toxicity observed
- Newer filing states plan to meet with FDA in second half of 2026 regarding accelerated regulatory pathway for fourth-line colorectal cancer and first-line registrational trial
- Newer filing provides March 2026 Ewing sarcoma update with 31 evaluable patients, 64.5% ORR, 87.1% disease control rate, with responses ongoing in eight patients
- Newer filing states plan to complete Ewing sarcoma enrollment in second half of 2026 and meet with FDA regarding accelerated regulatory pathway if trends continue
- Newer filing states biologics license application submitted to FDA in April 2026 for chondrosarcoma (vs. plan to submit in Q2 2026 in older filing)
- Newer filing mentions May 2026 announcement of positive interim results from randomized first-line Phase 2 HexAgon study for INBRX-106
- Removed:
- Older filing contains extensive discussion of separation from Former Parent (Inhibrx, Inc.), spin-off of INBRX-101, merger with Sanofi subsidiary, and related restructuring transactions - removed in newer filing
- Older filing states chondrosarcoma trial completed full enrollment in July 2025 - not mentioned in newer filing
- Older filing provides detailed chondrosarcoma safety information including hepatotoxicity discussion, fatal event early in study, mitigation measures, 11.8% vs 4.5% treatment-related hepatic adverse events - not included in newer filing
- Older filing references January 2025 interim colorectal adenocarcinoma data with 10 of 13 evaluable patients and mention of one complete response - removed in newer filing with updated April 2026 data
- Reworded:
- Older filing lists indications as 'chondrosarcoma, colorectal cancer, Ewing sarcoma, and certain other solid tumor types' vs. newer filing listing 'colorectal cancer, Ewing sarcoma, chondrosarcoma, and certain other solid tumor types' (reordered)
- Newer filing describes chondrosarcoma trial as 'randomized, blinded, placebo-controlled, registrational trial' vs. older filing's 'registration-enabling Phase 2 trial'
- Newer filing refers to disease as 'locally advanced or metastatic, unresectable colorectal cancer' vs. older filing's 'advanced or metastatic, unresectable colorectal adenocarcinoma'
- Notes:
- Newer filing text is truncated at end of INBRX-106 section, limiting complete comparison of that program's discussion
- Older filing provides substantially more background on corporate separation/restructuring which is entirely absent from newer filing, suggesting different filing periods and company circumstances rather than content changes to program information
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
14 open-market purchases and 5 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 30 days · read to 2026-10-046 buys ($2M) · 3 sells ($163543) — 2 buying, 1 selling insiders
- Last 90 days · read to 2026-10-0414 buys ($5M) · 5 sells ($279010) — 3 buying, 1 selling insiders
- Last 180 days · read to 2026-10-0414 buys ($5M) · 5 sells ($279010) — 3 buying, 1 selling insiders
Cluster buying: 3 different insiders reported open-market purchases (SEC code P) of INBX within a 30-day window between 2026-09-08 and 2026-09-28. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-28. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about INBX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
6 institutional 13F filers reported holding INBX as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 2,739,094
- Reported value $259,529,177
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about INBX's institutional holders → See what each manager we track holds →
Short interest (FINRA)
INBX had 3,393,511 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
INBX had 23.1% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 8.31 days to cover at the same settlement.
- Reported short interest (shares) 3,393,511
- Short interest (% of shares outstanding) 23.1%
- Prior settlement (shares) 3,297,743
- Reported change 2.9%
- Days to cover (reported) 8.31
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Amgen (AMGN)
- Regeneron Pharmaceuticals (REGN)
- BioMarin Pharmaceutical (BMRN)
- Vertex Pharmaceuticals (VRTX)
- Gilead Sciences (GILD)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare INBX vs…
INHIBRX BIOSCIENCES INC is found in…
Frequently asked questions
What does INHIBRX BIOSCIENCES INC (INBX) do?
Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on the development of therapeutic candidates for conditions with high unmet medical needs. The company utilizes its proprietary protein engineering platform to create novel biologics, including multivalent antibodies and therapeutic proteins.
What sector is INHIBRX BIOSCIENCES INC (INBX) in?
INHIBRX BIOSCIENCES INC (INBX) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are INHIBRX BIOSCIENCES INC's (INBX) competitors?
Notable peers of INHIBRX BIOSCIENCES INC (INBX) include Amgen, Regeneron Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Gilead Sciences. This peer set is informational only — not financial advice.
Is INHIBRX BIOSCIENCES INC (INBX) overbought or oversold right now?
INHIBRX BIOSCIENCES INC (INBX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 36, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on INBX come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.